

Press Release

ProStrakan Group Announces Canadian Launch of Abstral

Galashiels, UK – 14th June 2011: - ProStrakan Group plc, a subsidiary of Kyowa Hakko Kirin Co. Ltd., and an international specialty pharmaceutical company, announces today the launch in Canada of Abstral[®] by its Canadian partner, Paladin Labs Inc.

Abstral is a novel, rapidly-disintegrating, sublingual (under the tongue) formulation of fentanyl, a well-established opioid used for the management of breakthrough pain for cancer patients already receiving, and tolerant to, opioid analgesics for chronic pain. Abstral will be promoted in Canada alongside Paladin's other pain products which include: Tridural[®], Metadol[®] and Pennsaid[®].

ProStrakan outlicensed the Canadian rights to Paladin in December 2008 and Abstral was granted Canadian regulatory approval in February 2011.

Abstral is already marketed by ProStrakan across the principal European markets and was launched earlier this year in the United States. In the top four European markets, Abstral achieved a 24% market share by tablet volume of short-acting fentanyl products (Source: IMS data February 2011).

Breakthrough cancer pain ("BTP") is defined as rapid onset and short duration exacerbations of severe pain experienced by patients who have relatively stable and adequately controlled baseline pain.¹ It is known as BTP because it "breaks through" a regular pain medicine schedule.

¹ Portenoy RK, Hagen NA. Pain 1990; 41: 273-281

² Portenoy RK et al. Pain 1999; 81(1-2):129-134

For some patients, BTP occurs during certain everyday activities, such as walking or dressing. For others, it occurs unexpectedly without any apparent cause. Between 64% and 89% of patients with cancer experience BTP and they average 4 to 7 episodes per day.²

For further enquiries, please contact:

ProStrakan	+44 (0)1896 664000
Peter Allen, Chairman	
Allan Watson, Chief Financial Officer	
Callum Spreng, Corporate Communications	

About ProStrakan:

ProStrakan Group plc is a rapidly growing specialty pharmaceutical company engaged in the development and commercialisation of prescription medicines for the treatment of unmet therapeutic needs in major markets.

ProStrakan is a subsidiary of Kyowa Hakko Kirin Co. Ltd., the Japan-based global specialty pharmaceutical company.

ProStrakan's head office is located in Galashiels in Scotland. The company's development capabilities are centered in Galashiels and Bedminster, New Jersey, USA. Sales and marketing of ProStrakan's portfolio of products are handled by commercial subsidiaries in the UK, US, France, Germany, Spain, Italy and other EU countries.

You can learn more about the business at: www.prostrakan.com